

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2020 January 6; 8(1): 208-216

DOI: 10.12998/wjcc.v8.i1.208 ISSN 2307-8960 (online)

CASE REPORT

# Sarcomatoid intrahepatic cholangiocarcinoma mimicking liver abscess: A case report

Yan Wang, Jia-Lei Ming, Xing-Yu Ren, Lu Qiu, Li-Juan Zhou, Shu-Dong Yang, Xiang-Ming Fang

**ORCID number:** Yan Wang (0000-0002-5151-922X); Jia-Lei Ming (0000-0002-3536-4694); Xing-Yu Ren (0000-0001-6122-6837); Lu Qiu (0000-0001-5510-9589); Li-Juan Zhou (0000-0001-5384-2971); Shu-Dong Yang (0000-0001-8894-9314); Xiang-Ming Fang (0000-0003-2961-0809).

Author contributions: Wang Y designed the work, analyzed and interpreted the data and prepared the manuscript; Ming JL, Ren XY, Qiu L and Zhou LJ collected clinical data and edited the manuscript; Yang SD analyzed the pathological data; Fang XM was responsible for revision of the manuscript. All authors read and approved the final manuscript.

Supported by National Natural Science Foundation of China, No. 81271629; Medical Innovation Team of Wuxi City, No. CXTD002.

Informed consent statement: This report was approved by the ethics committee and the patients provided written informed consent.

#### CARE Checklist (2016) statement:

The manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, Yan Wang, Jia-Lei Ming, Xing-Yu Ren, Lu Qiu, Li-Juan Zhou, Xiang-Ming Fang, Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, Jiangsu Province, China

Shu-Dong Yang, Department of Pathology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, Jiangsu Province, China

Corresponding author: Xiang-Ming Fang, MD, PhD, Chief Doctor, Instructor, Professor, Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, No. 299 Qingyang Road, Wuxi 214023, Jiangsu Province, China. xiangming fang@njmu.edu.cn

## **Abstract**

#### **BACKGROUND**

Sarcomatoid intrahepatic cholangiocarcinoma (SICC) is an extremely rare and highly invasive malignant tumor of the liver. To our knowledge, the imaging findings of sarcomatous cholangiocarcinoma have been rarely reported; and radiological features of this tumor mimicking liver abscess have not yet been reported.

## CASE SUMMARY

We present a case of SICC mimicking liver abscess. The patient, a 43-year-old male, complained of repeated upper right abdominal discomfort and intermittent distension over a period of one month. Radiology examination revealed a huge focal lesion in the right liver. The lesion was hypointense on computed tomography with honeycomb enhancement surrounded by enhanced peripheral areas. It showed a hypo-signal on non-contrast T1-weighted images and a hypersignal on non-contrast T2-weighted images. Radiologists diagnosed the lesion as an atypical liver abscess. The patient underwent a hepatectomy. After surgery, he survived another 2.5 mo before passing away. A search of PubMed and Google revealed 43 non-repeated cases of SICC reported in 20 published studies. The following is a short review in order to improve the diagnostic and therapeutic skills in cases of SICC.

#### **CONCLUSION**

This report presents the clinical and radiological features of SICC and imaging features which showed hypovascularity and progressive enhancement. SICC can present as a multilocular cyst on radiological images and it is necessary to distinguish this lesion from an atypical abscess. Simple surgical treatment is not the best treatment option for this disease.

and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licen ses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Received: October 10, 2019 Peer-review started: October 10,

First decision: November 13, 2019 Revised: November 26, 2019 Accepted: November 30, 2019 Article in press: November 30, 2019 Published online: January 6, 2020

P-Reviewer: Anand A, Isik A, Ramia J, Rungsakulkij N, Valek V

**S-Editor:** Zhang L L-Editor: Webster JR E-Editor: Qi LL



**Key words:** Sarcomatoid intrahepatic cholangiocarcinoma; Liver abscess; Radiological features; Case report

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Sarcomatoid intrahepatic cholangiocarcinoma (SICC) is an extremely rare and highly invasive malignant tumor of the liver. The radiological features of this lesion have been rarely reported and it is difficult to differentiate this tumor from a liver abscess. We present the clinical, radiological characteristics and treatment of a patient with SICC followed by a summary of relevant English literature regarding this condition, including a prognosis analysis of SICC.

Citation: Wang Y, Ming JL, Ren XY, Qiu L, Zhou LJ, Yang SD, Fang XM. Sarcomatoid intrahepatic cholangiocarcinoma mimicking liver abscess: A case report. World J Clin Cases 2020; 8(1): 208-216

URL: https://www.wjgnet.com/2307-8960/full/v8/i1/208.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v8.i1.208

## INTRODUCTION

Sarcomatous cholangiocarcinoma is a rare intrahepatic malignant tumor, accounting for 4.5% of intrahepatic cholangiocarcinomas[1]. Spindle-shaped and pleomorphic cells and adenoid structures are observed in sarcomatous cholangiocarcinoma<sup>[1]</sup>. In the relevant literature, it is also known as cholangiocarcinoma with sarcomatous changes<sup>[2]</sup>. The tumor pathogenesis has not been sufficiently clarified. The prognosis of sarcomatous cholangiocarcinoma is worse than that of conventional cholangiocarcinoma<sup>[1]</sup>. Pathological diagnosis is the gold standard for diagnosing sarcomatous cholangiocarcinoma. However, a preoperative biopsy can lead to intratumor bleeding and dissemination<sup>[2]</sup>. It is imperative to improve the preoperative diagnosis using imaging examination. To our knowledge, the imaging findings of sarcomatous cholangiocarcinoma have rarely been reported, nor have its radiological features mimicking liver abscess. We report a patient with intrahepatic sarcomatoid cholangiocarcinoma (SICC) and discuss the imaging and clinical features of this unusual disease through a careful review of the literature.

#### CASE PRESENTATION

#### Chief complaints

The patient was a 43-year-old male suffering from repeated upper right abdominal discomfort and intermittent distension over a period of one month. There was no report of radiation of the pain to his shoulder and back.

## History of present illness

There was neither a history nor symptoms of fever, yellowish eyes, weight loss, or vomiting.

#### History of past illness

He had a 25-year history of hepatitis B. He did not take any routine medication.

### Personal and family history

His medical and family history did not reveal any history of serious or terminal illnesses or any other relevant information.

## Physical examination upon admission

His temperature was 37°C, resting heart rate was 80 bpm, respiratory rate was 15 breaths/min, and blood pressure was 120/80 mmHg.

## Laboratory examinations

The results of blood analysis were as follows: Red blood cells,  $5.08 \times 10^{12}/L$  [normal range:  $(3.5-5.5) \times 10^{12}/L$ ]; white blood cells,  $7.7 \times 10^9/L$  [normal range:  $(4-10) \times 10^{12}/L$ ], and platelet count, 149 × 10°/L [normal range: (80-300) × 10°/L]. The results of liver function tests were as follows: Albumin, 39.3 g/L [normal range: (35.0-53.0) g/L]; globulin, 25.5 g/L [normal range: (17.0-33.5) g/L]; lactic dehydrogenase, 181.0 U/L [normal range: (109.0-245.0) U/L]. The results of C-reactive protein and procalcitonin were 4 mg/L [normal range: (0-8) mg/L] and 0.04 ng/mL [normal range: (0-0.5) ng/mL], respectively. Other measurements were as follows: Serum α-fetoprotein (AFP) 66.91 ng/mL (normal range < 10 ng/mL), carcinoembryonic antigen 1.02 ng/mL (normal range < 5 ng/mL), serum carbohydrate antigen (CA) 19-9 and CA 125 levels were 19.9 U/mL and 26.3 U/mL (normal range: < 35 U/mL), respectively.

#### Imaging examinations

An abnormal mass of hypointensity on T1-weighted images (T1WI) and hyperintensity on T2-weighted images (T2WI) was observed in the right liver lobe (Figure 1). On post-contrast T1WI, honeycomb-like continuous enhancement, with slight transient hepatic parenchymal enhancement (THPE) around it, and adjacent proximal bile duct dilatation with enhancement of the wall were observed. In the arterial phase, blood vessels could be seen entering the lesion. Initially, a hepatic abscess could not be excluded. Further computed tomography (CT) examination (Figure 2) showed that the right lobe of the liver had a patchy low-density lesion of approximately 7.0 cm × 5.6 cm with heterogeneous enhancement. Mild dilation of the intrahepatic bile duct and enlarged lymph nodes of the retroperitoneal region were observed.

The diagnosing physician considered it to be a malignant occupation; thus, surgical resection was performed. During the operation, no ascitic fluid was found in the abdominal cavity. The liver was reddish-brown and nodular hyperplasia of the liver could be seen. A mass in the right lobe of the liver was observed, which had a hard texture. In addition, no satellite lesions were found around this mass. The surgeon diagnosed it as liver cancer and performed radical hepatectomy and lympha-

The gross cross-section examination revealed a yellowish-white mass. On microscopic examination, the tumor consisted of an adenocarcinoma component and a sarcomatous component, and the background liver showed nodular hyperplasia. Immunohistochemical examination of the mass revealed positive staining for CD34, CK19, and pancytokeratin AE1/AE3, and negative staining for CA19, hepatocytes, AFP, HMBE-1, G3, TG, TTF1, and CK5/6.

## FINAL DIAGNOSIS

Based on the histological and immunohistochemical findings, the tumor was diagnosed as an intrahepatic less differentiated sarcomatoid cholangiocarcinoma.

#### TREATMENT

The patient underwent radical hepatectomy. After surgery, he was treated with antiinfection agents, rehydration, and symptomatic treatment.

## OUTCOME AND FOLLOW-UP

The overall duration of follow-up was only 2.5 mo as the patient passed away.

## DISCUSSION

Sarcomatous changes that occur in cholangiocarcinoma are considered rare and the World Health Organization [3] classification of tumors defines sarcomatous intrahepatic cholangiocarcinoma (SICC) as a cholangiocarcinoma with spindle cell areas resembling spindle cell sarcoma or fibrosarcoma or with features of malignant fibrous histiocytoma. At present, the specific pathological mechanism of cholangiocarcinoma with sarcomatosis has not been clarified. Clinical manifestations as well as radiological imaging of this tumor are still limited.

An internet research was carried out using the search engines PubMed and Google with the keywords: "liver", "sarcomatous", "sarcomatoid", "sarcomatosis" and "cholangiocarcinoma". References of related literature were also reviewed to identify any other potentially relevant publications. After detailed search and analysis, 43 nonrepeated cases of SICC were identified in 20 published studies<sup>[1,2,4-20]</sup>.




Figure 1 Magnetic resonance imaging results. A-B: There is an abnormal lesion occupying the right lobe of the liver, hyperintense on non-contrast T2 weighted images and hypointense on non-contrast T1 weighted images; C-E: A honeycomb-like structure and persistent enhancement with slight transient hepatic parenchymal enhancement around it and adjacent proximal bile duct dilatation with enhancement of the wall on contrast-enhanced T1 weighted images were observed.

The following tables (Tables 1-3) present a summary of the previous Englishlanguage literature with the addition of the present case. The clinical features of SICC were non-specific. Abdominal pain and fever were the most common complaints in patients. The age of the patients ranged from 37 to 87 years (median age, 61.5 years) with SICC being more commonly observed in men. This is consistent with the age and sex of the patient in the current study. Similar to typical cholangiocarcinoma, SICC usually occurs in the left lobe of the liver.

Radiologic imaging of SICC is still limited. It usually shows a clear low or mixed echo mass on ultrasound[21]. CT examination revealed low density lesions, clear or unclear, and sometimes with intra-tumor hemorrhage<sup>[15]</sup>. Most lesions had enhanced peripheral areas in the arterial phase and gradually filled in the central region. In our case, on CT analysis, the lesion was seen as a patchy low-density mass with an unclear boundary. Heterogeneous enhancement was observed in peripheral areas, with no obvious enhancement in the inner necrosis area. In addition, there was slight THPE around the mass. As a result, it is difficult to distinguish SICC from an atypical liver abscess. It was reported that satellite foci may appear in SICC; and there is a certain relationship between satellite nodules and SICC<sup>[14]</sup>. In the case reported herein, no daughter nodules were found. On magnetic resonance imaging, the lesion had low signal on T1WI and high signal on T2WI. After enhancement, a honeycomb-like structure and persistent enhancement with slight THPE and adjacent proximal bile duct dilatation with enhancement of the wall were observed. In addition, blood vessels were observed entering the lesion, which was also considered a distinguishing feature. The SICC involved multiple cystic changes accompanied by fibrous septum and was inhomogeneous and hyperintense in the center on DWI mapping, which was similar to atypical liver abscess on DWI mapping<sup>[18]</sup>. Unfortunately, our patient had no evidence of diffusion restriction. Abdominal angiography showed that the tumor was supplied by the hepatic artery and was considered anemic<sup>[7]</sup>, which was consistent with the results after enhancement.

The degree of SICC malignancy is higher than that of traditional cholangiocarcinoma. The general prognosis for this malignancy is 3 mo<sup>[1]</sup>. It may be associated with an intrinsic sarcoma-like component, with high invasiveness. Most of these tumors are removed by surgery, and there is no unified comprehensive treatment for them. A previous study reported that surgery and postoperative treatment of a combination of gemcitabine and cisplatin adjuvant therapy can improve the prognosis of patients, and survival can be as long as 29 mo[13]. However,




Figure 2 Computed tomography images and histopathologic findings (100 ×). A-C: The right lobe of the liver shows a patchy low-density shadow of approximately 7.0 cm × 5.6 cm with heterogeneous enhancement on magnetic resonance imaging; D: The cells are spindle to round in shape, with scanty cytoplasm and hyperchromatic nuclei, forming nests and microglandular structures.

the effectiveness of chemotherapy remains unclear. According to the survival curve (Figure 3), using the Kaplan-Meier method, in 44 patients with SICC reported in the literature and our case, the survival rate of patients who underwent surgery was significantly higher than those without surgery. The present patient did not undergo chemotherapy or radiotherapy after surgery, only supportive treatment. This was likely a contributing factor in his postoperative survival time of only 2.5 mo.

## CONCLUSION

In summary, the clinical and radiological features of SICC are non-specific. The usual symptoms are abdominal pain and fever and the imaging features are hypovascularity and progressive enhancement. SICC can present as a multilocular cyst on radiological images and it is necessary to distinguish it from an atypical abscess. It is very difficult to diagnose SICC accurately prior to surgery. The last necessary preoperative biopsy is used for identification. Pathological diagnosis is the gold standard for diagnosing SICC. We report a case of SICC mimicking liver abscess and previous reports were reviewed to increase our understanding of the clinical and imaging evidence of SICC in order to improve the preoperative diagnostic ability for radiologists as well as surgeons.

Table 1 Summary of sarcomatous intrahepatic cholangiocarcinoma reported in English-language literature from 1992 to 2019

Nakajima et al	Ref.	Case No.	Age/sex	Clinical symptom	Location	Size (cm)	Treatment	Outcome (mo
1	Nakajima <i>et al</i> <sup>[1]</sup>	1	84/F	jaundice,	Hepatic hilum	3.5	None	Died 3
Abdominat    Abdominat    Left lobe   10.0   None   Died 2.5		2	45/F	Fever	Right lobe	14.0	Surgery	Died 4.5
		3	73/F	Abdominal mass	Left lobe	7.0	Chemotherapy	Died 5
		4	37/M	discomfort,	Left lobe	10.0	None	Died 2.5
Nypochondralgia   Nypochondr		5	64/M	discomfort,	Left lobe	7.5	TAE	Died 1
Haratake et at		6	52/M		Right lobe	7.5	TAE	Died 2
Haratake et alicia		7	69/M	Fever	Left lobe	10.0	Surgery	Well 36
Abdominal mass   Abdo	Inoue <i>et al</i> <sup>[2]</sup>	8	61/M	•	Left lobe	25.0	Surgery	Died 1.1
Honda et al	Haratake et al <sup>[4]</sup>	9	59/M		Hepatic hilar	NA	Supportive	Died 1
Matsuo et ali 1 2 77/F Abdominal pain Left lobe 4.3 Surgery Died 5 Istambot et ali 1 3 70/M Fatigue, fever Right lobe 8.0 Surgery Well 9 (Stambor) et ali 1 1 60/F Fever, abdominal Left lobe 20.0 Surgery Died 3 pain 1 1 6 Fever, abdominal Left lobe 20.0 Surgery Died 3 pain 1 1 6 Fever, abdominal Left lobe 20.0 Surgery Died 3 Point et ali 1 1 6 Fever, abdominal Left lobe 20.0 Surgery Alive 2 Point et ali 1 1 6 Fever, abdominal Left lobe 20.0 Surgery Alive 2 Point et ali 1 1 7 Fever, abdominal pain Left lobe 20.0 Surgery Alive 2 Point et ali 1 1 7 Fever, abdominal pain Left lobe 20.0 Surgery Alive 2 Point enzyme levels Abdominal pain Left lobe 20.0 Surgery and Well 29 Chemotherapy Rolling et ali 1 1 9 Fever, abdominal pain Left lobe 20.0 Surgery and Point Pain, dizziness, mild fever Right lobe 20.0 Surgery and Well 29 Chemotherapy Rolling et ali 1 2 6 Fever, abdominal pain Left lobe 20.0 Surgery and Point Pain, dizziness, mild fever Right lobe 20.0 Surgery and Well 8 Chemotherapy Rolling et ali 1 2 6 Fever, abdominal pain Left lobe 20.0 Surgery and Point Pain, dizziness, mild fever Right lobe 20.0 Surgery and Well 8 Chemotherapy Rolling et ali 1 2 6 Fever, abdominal pain Left lobe 20.0 Surgery and Well 8 Chemotherapy Rolling et ali 1 2 6 Fever, abdominal pain Left lobe 20.0 Surgery and Well 8 Chemotherapy Rolling et ali 1 2 6 Fever Right lobe 20.0 Surgery Alive 6 Fever Right lobe 20.0 Surgery Alive 6 Fever Right lobe 20.0 Surgery Alive 6 Fever Right lobe 20.0 Surgery Died 2 Fever Right lobe 20.0 Surgery Died 4 8 Fever Right lobe 20.0 Surgery Right lobe	Imazu et al <sup>[5]</sup>	10	77/M	Liver tumor	Left lobe	7.0	Surgery	NA
Ramoto et al   13	Honda et al <sup>[6]</sup>	11	61/F	Back pain	0	NA	Supportive	Died 3.8
Kaibori et ali	Matsuo et al <sup>[7]</sup>	12	77/F	Abdominal pain	Left lobe	4.3	Surgery	Died 5
Supplemental   Supp	Itamoto et al <sup>[8]</sup>	13	70/M	Fatigue, fever	Right lobe	8.0	Surgery	Well 9
Lim et al	Kaibori <i>et al<sup>[9]</sup></i>	14	69/F		Left lobe	20.0	Surgery	Died 3
Part	Gupta et al <sup>[10]</sup>	15	50/M	Jaundice	Hepatic hilum	2.0	NA	NA
Malhotra et al   18	Lim et al <sup>[11]</sup>	16	41/F	•	Left lobe	17.0	Surgery	Alive 2
Bilgin et al   19	Sato <i>et al</i> <sup>[12]</sup>	17	87/M		Left lobe	4.0	Supportive	Died 3
Fatigue   Fatigue   Chemotherapy   Chemotherapy   Fatigue   Pain, dizziness, mild fever   Right lobe   Righ	Malhotra <i>et al</i> <sup>[13]</sup>	18	60/F	•	Left lobe	20.0	0 ,	Well 29
Watanabe et al [19]21 $62/M$ Liver tumor, jaundiceHepatic hilum, jaundice $4.5$ Surgery and chemotherapyDied 11 chemotherapyKim et al [19]22 $67/M$ Abdominal painLeft lobe $6.0$ SurgeryAlive $6$ Shi et al [19]23 $55/M$ NARight lobeNASurgeryDied $2$ Zhang et al [19]25 $63/M$ Abdominal painLeft lobeNASurgeryWell $4$ Zhang et al [20]26 $45/M$ Abdominal painNA $7.5$ ChemotherapyDied $1.6$ $27$ $67/M$ Abdominal painNA $2.5$ ChemotherapyDied $4.9$ $28$ $55/M$ Abdominal painNA $6.5$ ChemotherapyDied $4.9$ $28$ $55/M$ Abdominal painNA $10.0$ SupportiveDied $0.7$ $29$ $66/M$ Abdominal painNA $10.0$ SupportiveDied $0.7$ $29$ $66/M$ Abdominal painNA $10.0$ SupportiveDied $0.7$ $30$ $56/M$ Abdominal painNA $7.5$ ChemotherapyDied $0.7$ $31$ $66/M$ Abdominal painNA $7.5$ ChemotherapyDied $0.7$ $32$ $68/M$ BWL, fatigueNA $6.0$ SupportiveDied $0.6$ $33$ $55/M$ Abdominal painNA $9.5$ ChemotherapyDied $0.6$ $34$ $49/M$ Abdominal painNA $9.5$ Chemotherapy $F/U$ $40$ $40$ <	Bilgin et al <sup>[14]</sup>	19	48/M		Left lobe	13.0		Alive 12
	[ung et al <sup>[15]</sup>	20	59/M		Right lobe	18.0	0 ,	Well 8
Shi et al   18]   23   55/M   NA   Right lobe   NA   Surgery   Died 2		21	62/M		Hepatic hilum	4.5	0 ,	Died 11
24	Kim et al <sup>[17]</sup>	22	67/M	Abdominal pain	Left lobe	6.0	Surgery	Alive 6
Zhang et al <sup>[19]</sup> 25         63/M         Abdominal pain         Left lobe         NA         Surgery         Well 4           Kim et al <sup>[20]</sup> 26         45/M         Abdominal pain         NA         7.5         Chemotherapy         Died 1.6           27         67/M         Abdominal pain         NA         2.5         Chemotherapy         Died 4.9           28         55/M         Abdominal pain, fever         NA         6.5         Chemotherapy         Died 4.3           29         66/M         Abdominal pain, fever         NA         10.0         Supportive         Died 0.7           30         56/M         Abdominal pain, fatigue         NA         8.0         Chemotherapy         Died 2.4           31         66/M         Abdominal pain         NA         7.5         Chemotherapy         Died 4.2           32         68/M         BWL, fatigue         NA         6.0         Supportive         Died 0.6           33         55/M         Abdominal pain, fever         NA         8.5         Chemotherapy         Died 1           34         49/M         Abdominal pain, fever         NA         9.5         Chemotherapy         F/U           35         65/M	Shi et al <sup>[18]</sup>	23	55/M	NA	Right lobe	NA	Surgery	Died 2
Kim et al2645/MAbdominal painNA7.5ChemotherapyDied 1.62767/MAbdominal painNA2.5ChemotherapyDied 4.92855/MAbdominal pain, feverNA6.5ChemotherapyDied 4.32966/MAbdominal pain, feverNA10.0SupportiveDied 0.73056/MAbdominal pain, fatigueNA8.0ChemotherapyDied 2.43166/MAbdominal painNA7.5ChemotherapyDied 4.23268/MBWL, fatigueNA6.0SupportiveDied 0.63355/MAbdominal pain, feverNA8.5ChemotherapyDied 13449/MAbdominal pain, feverNA9.5ChemotherapyF/U3565/MAbdominal painNA9.5SupportiveDied 0.5		24	47/M	NA	Right lobe	NA	Surgery	Died 6
27 67/M Abdominal pain NA 2.5 Chemotherapy Died 4.9 28 55/M Abdominal pain, NA 6.5 Chemotherapy Died 4.3 fever 29 66/M Abdominal pain, NA 10.0 Supportive Died 0.7 fever 30 56/M Abdominal pain, NA 8.0 Chemotherapy Died 2.4 fatigue 31 66/M Abdominal pain NA 7.5 Chemotherapy Died 4.2 32 68/M BWL, fatigue NA 6.0 Supportive Died 0.6 33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1 fever 34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U fever 35 65/M Abdominal pain, NA 9.5 Supportive Died 0.5	Zhang et al <sup>[19]</sup>	25	63/M	Abdominal pain	Left lobe	NA	Surgery	Well 4
28 55/M Abdominal pain, NA 6.5 Chemotherapy Died 4.3 fever 29 66/M Abdominal pain, NA 10.0 Supportive Died 0.7 fever 30 56/M Abdominal pain, NA 8.0 Chemotherapy Died 2.4 fatigue 31 66/M Abdominal pain NA 7.5 Chemotherapy Died 4.2 32 68/M BWL, fatigue NA 6.0 Supportive Died 0.6 33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1 fever 34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U fever 35 65/M Abdominal pain NA 9.5 Supportive Died 0.5	Kim et al <sup>[20]</sup>	26	45/M	Abdominal pain	NA	7.5	Chemotherapy	Died 1.6
fever  29 66/M Abdominal pain, NA 10.0 Supportive Died 0.7 fever  30 56/M Abdominal pain, NA 8.0 Chemotherapy Died 2.4 fatigue  31 66/M Abdominal pain NA 7.5 Chemotherapy Died 4.2  32 68/M BWL, fatigue NA 6.0 Supportive Died 0.6  33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1 fever  34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U fever  35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		27	67/M	Abdominal pain	NA	2.5	Chemotherapy	Died 4.9
fever  30 56/M Abdominal pain, NA 8.0 Chemotherapy Died 2.4 fatigue  31 66/M Abdominal pain NA 7.5 Chemotherapy Died 4.2  32 68/M BWL, fatigue NA 6.0 Supportive Died 0.6  33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1  fever  34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U  fever  35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		28	55/M	•	NA	6.5	Chemotherapy	Died 4.3
fatigue  31 66/M Abdominal pain NA 7.5 Chemotherapy Died 4.2  32 68/M BWL, fatigue NA 6.0 Supportive Died 0.6  33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1  fever  34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U  fever  35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		29	66/M	•	NA	10.0	Supportive	Died 0.7
32 68/M BWL, fatigue NA 6.0 Supportive Died 0.6 33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1 fever 34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U fever 35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		30	56/M	•	NA	8.0	Chemotherapy	Died 2.4
33 55/M Abdominal pain, NA 8.5 Chemotherapy Died 1 fever  34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U fever  35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		31	66/M	Abdominal pain	NA	7.5	Chemotherapy	Died 4.2
fever  34 49/M Abdominal pain, NA 9.5 Chemotherapy F/U fever  35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		32	68/M	BWL, fatigue	NA	6.0	Supportive	Died 0.6
fever  35 65/M Abdominal pain NA 9.5 Supportive Died 0.5		33	55/M		NA	8.5	Chemotherapy	Died 1
		34	49/M	•	NA	9.5	Chemotherapy	F/U
36 61/M Abdominal pain NA 5.0 Viscum album Alive 12.7		35	65/M	Abdominal pain	NA	9.5	Supportive	Died 0.5
		36	61/M	Abdominal pain	NA	5.0	Viscum album	Alive 12.7

Wang Y  ${\it et\,al.}$  Case of sarcomatoid intrahepatic cholangiocarcinoma

Tsou et al <sup>[21]</sup>	37	77/F	Abdominal pain, palpable mass, BWL	Left lobe	14.0	None	Died 2
	38	62/M	Abdominal pain, BWL	Right lobe	3.0	Unknown	F/U
	39	59/M	Abdominal pain, palpable mass, BWL	Left lobe	11.0	None	Died 1
	40	63/M	Dyspnea, BWL	Right lobe	14.0	None	Died 0.3
	41	64/M	Back pain	Left lobe	11.0	Surgery	Died 2
	42	50/F	Abdominal pain	Right lobe	4.5	Surgery	Died 2
	43	69/F	Abdominal pain, fever	Left lobe	2.5	Surgery	Alive 48
Our case	44	43/M	Abdominal discomfort	Right lobe	7.0	Surgery	Died 2.5

F: Female; M: Male; BWL: Body weight loss; TAE: Transarterial embolization; NA: Not available; F/U: Lost to follow-up.

Table 2 Clinical characteristics of sarcomatous intrahepatic cholangiocarcinoma reported in the English-language reports and our case

Clinical characteristics	Number
Age (yr) <sup>1</sup>	60.8 ± 11.3, 61.5
Gender (Male/Female)	33:11 (3:1)
Clinical symptoms	
Abdominal pain/discomfort	26/44 (59.1%)
Fever	11/44 (25.0%)
Abdominal mass	6/44 (13.6%)
Jaundice	4/44 (9.0%)
Digestive symptoms	2/44 (4.5%)
Fatigue	4/44 (9.0%)
Back pain	2/44 (4.5%)
Body weight loss	4/44 (9.0%)
Dizziness	1/44 (2.3%)
None	2/44 (4.5%)

 $<sup>^{1}</sup>$ Values for age are presented as means  $\pm$  SD (n = 44) and median.

2/3 (66.7%)

Table 3 Summary of rac	liological features of 44 patients			
		Radiological features	Number	
Location		Left lobe	18/44 (40.9%)	
		Right lobe	10/44 (22.7%)	
		Hepatic hilum	4/44 (9.0%)	
		Multiple	1/44 (2.3%)	
		Unknown	11/44 (25.0%)	
Tumor size (cm) <sup>1</sup>			$9.0 \pm 5.2$	
US		Hypoechoic	6/23 (26.1%)	
		Hyperechoic	3/23 (13.0%)	
		Mixed-echoic	10/23 (45.5%)	
		Unseen	1/23 (4.3%)	
		Unknown	3/23 (13.0%)	
CT	Plain	Low density	19/19 (100%)	
	Enhancement	Enhanced peripheral areas	22/23 (95.7%)	
		(progressive enhancement to the central region)	(12/23) (52.2%)	
		Without enhancement	1/23 (4.3%)	
MRI	T1 WI	Iso/Low intensity	6/8 (75.0%)	
	T2 WI	High intensity border	1/8 (12.5%)	
		High and low intensity	5/8 (62.5%)	
	Unknown		2/8 (25.0%)	
	Enhancement	Enhanced peripheral areas	2/8 (25.0%)	
		(progressive enhancement to the central region)	(2/8) (25.0%)	
	Unknown		6/8 (75.0%)	
Angiography		Hypovascularity	1/3 (33.3%)	

Unknown

 $<sup>^{1}</sup>$ Values for tumor size are presented as means  $\pm$  SD (n = 44). CT: Computed tomography; MRI: Magnetic resonance imaging.s




Figure 3 Survival rates of operated sarcomatous intrahepatic cholangiocarcinoma and non-operative sarcomatous intrahepatic cholangiocarcinoma. Survival rates of 44 cases of sarcomatous intrahepatic cholangiocarcinoma (SICC) calculated by Kaplan-Meier method [operated SICC (black solid line) and nonoperative SICC (grey solid line)] are shown. The difference was estimated using the generalized log-rank method. P values of less than 0.05 are considered statistically significant.

#### **ACKNOWLEDGEMENTS**

We are grateful to our foreign teacher, a Canadian, for his contribution to language polishing and thank the patients and their family members who agreed to publish this

## REFERENCES

- Nakajima T, Tajima Y, Sugano I, Nagao K, Kondo Y, Wada K. Intrahepatic cholangiocarcinoma with sarcomatous change. Clinicopathologic and immunohistochemical evaluation of seven cases. Cancer 1993; 72: 1872-1877 [PMID: 7689920 DOI: 10.1002/1097-0142(19930915)72:6<1872:]
- Inoue Y, Lefor AT, Yasuda Y. Intrahepatic cholangiocarcinoma with sarcomatous changes. Case Rep 2 Gastroenterol 2012; 6: 1-4 [PMID: 22379464 DOI: 10.1159/000335883]
- Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Switzerland: World Health Organization 2010; 417
- Haratake J. Yamada H. Horie A. Inokuma T. Giant cell tumor-like cholangiocarcinoma associated with systemic cholelithiasis. Cancer 1992; 69: 2444-2448 [PMID: 1314689 DOI: 10.1002/1097-0142(19920515)69:10<2444:aid-cncr2820691010>3.0.co;2-r]
- Imazu H, Ochiai M, Funabiki T. Intrahepatic sarcomatous cholangiocarcinoma. J Gastroenterol 1995; 30: 677-682 [PMID: 8574344 DOI: 10.1007/bf02367798]
- Honda M, Enjoji M, Sakai H, Yamamoto I, Tsuneyoshi M, Nawata H. Case report: intrahepatic cholangiocarcinoma with rhabdoid transformation. J Gastroenterol Hepatol 1996; 11: 771-774 [PMID: 77 DOI: 10.1111/j.1440-1746.1996.tb00330.x]
- Matsuo S, Shinozaki T, Yamaguchi S, Takami Y, Obata S, Tsuda N, Kanematsu T. Intrahepatic cholangiocarcinoma with extensive sarcomatous change: report of a case. Surg Today 1999; 29: 560-563 [PMID: 10385374 DOI: 10.1007/BF02482354]
- Itamoto T, Asahara T, Katayama K, Momisako H, Dohi K, Shimamoto F. Double cancer hepatocellular carcinoma and intrahepatic cholangiocarcinoma with a spindle-cell variant. J Hepatobiliary Pancreat Surg 1999; **6**: 422-426 [PMID: 10664295 DOI: 10.1007/s005340050144]
- Kaibori M, Kawaguchi Y, Yokoigawa N, Yanagida H, Takai S, Kwon AH, Uemura Y, Kamiyama Y. Intrahepatic sarcomatoid cholangiocarcinoma. J Gastroenterol 2003; 38: 1097-1101 [PMID: 14673730] DOI: 10.1007/s00535-003-1203-y]
- 10 Gupta K, Powari M, Dey P. Sarcomatous cholangiocarcinoma. Diagn Cytopathol 2003; 28: 168-169 [PMID: 12619101 DOI: 10.1002/dc.10259]
- Lim BJ, Kim KS, Lim JS, Kim MJ, Park C, Park YN. Rhabdoid cholangiocarcinoma: a variant of 11 cholangiocarcinoma with aggressive behavior. Yonsei Med J 2004; 45: 543-546 [PMID: 15227745 DOI: 10.3349/ymj.2004.45.3.543]
- 12 Sato K, Murai H, Ueda Y, Katsuda S. Intrahepatic sarcomatoid cholangiocarcinoma of round cell variant: a case report and immunohistochemical studies. Virchows Arch 2006; 449: 585-590 [PMID: 17033799] DOI: 10.1007/s00428-006-0291-5]
- Malhotra S, Wood J, Mansy T, Singh R, Zaitoun A, Madhusudan S. Intrahepatic sarcomatoid 13 cholangiocarcinoma. J Oncol 2010; 2010: 701476 [PMID: 20454704 DOI: 10.1155/2010/701476]
- Bilgin M, Toprak H, Bilgin SS, Kondakci M, Balci C. CT and MRI findings of sarcomatoid 14 cholangiocarcinoma. Cancer Imaging 2012; 12: 447-451 [PMID: 23092855 DOI: 10.1102/1470-7330.2012.0036]
- 15 Jung GO, Park DE, Youn GJ. Huge subcapsular hematoma caused by intrahepatic sarcomatoid cholangiocarcinoma. Korean J Hepatobiliary Pancreat Surg 2012; 16: 70-74 [PMID: 26388910 DOI:
- Watanabe G, Uchinami H, Yoshioka M, Nanjo H, Yamamoto Y. Prognosis analysis of sarcomatous 16 intrahepatic cholangiocarcinoma from a review of the literature. Int J Clin Oncol 2014; 19: 490-496 [PMID: 23824556 DOI: 10.1007/s10147-013-0586-x]
- Kim HM, Kim H, Park YN. Sarcomatoid cholangiocarcinoma with osteoclast-like giant cells associated with hepatolithiasis: A case report. Clin Mol Hepatol 2015; 21: 309-313 [PMID: 26523274 DOI: 10.3350/cmh.2015.21.3.309]
- Shi D, Ma L, Zhao D, Chang J, Shao C, Qi S, Chen F, Li Y, Wang X, Zhang Y, Zhao J, Li H. Imaging and 18 clinical features of primary hepatic sarcomatous carcinoma. Cancer Imaging 2018; 18: 36 [PMID: 30314525 DOI: 10.1186/s40644-018-0171-7]
- 19 Zhang N, Li Y, Zhao M, Chang X, Tian F, Qu Q, He X. Sarcomatous intrahepatic cholangiocarcinoma: Case report and literature review. Medicine (Baltimore) 2018; 97: e12549 [PMID: 30278551 DOI: 10.1097/MD.0000000000012549
- Kim DK, Kim BR, Jeong JS, Baek YH. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years. World J Gastroenterol 2019; 25: 608-621 [PMID: 30774275
- Tsou YK, Wu RC, Hung CF, Lee CS. Intrahepatic sarcomatoid cholangiocarcinoma: clinical analysis of seven cases during a 15-year period. Chang Gung Med J 2008; 31: 599-605 [PMID: 19241900]



Published By Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-2238242

E-mail: bpgoffice@wjgnet.com
Help Desk:https://www.f6publishing.com/helpdesk
https://www.wjgnet.com

